Raymond James initiated coverage of Maze Therapeutics (MAZE) with a Strong Buy rating and $48 price target Maze’s lead wholly-owned assets – MZE829 in Phase 2 study for APOL1-mediated kidney disease and MZE782 entering Phase 2 in phenylketonuria and CKD – target high unmet need chronic kidney disease populations and have “best-in-class potential,” the analyst tells investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MAZE:
- Maze Therapeutics Reports Strong Q3 2025 Progress
- Promising Developments in Maze Therapeutics’ Pipeline: Buy Rating Reinforced by MZE829 and MZE782 Advances
- Maze Therapeutics reports Q3 EPS (66c), consensus (69c)
- Maze Therapeutics Advances Kidney Disease Treatment with MZE829 Study
- Maze Therapeutics files to sell 9.23M shares of common stock for holders